Search research articles
Contact Us
Filters
Showing results (41-50 of 107) with videos related to
Page
of 11
Sort By:
European Journal of Orthodontics
|
January 22, 2022
A non-cephalometric two-dimensional appraisal of soft tissue changes by functional therapy in Class II patients: a systematic review and meta-analysis
Jonathan Luyten, Michiel Vierendeel, Noëmi M C De Roo, et al.
Cancer Treatment Reports
|
June 1, 1983
Vincristine in advanced bladder cancer: a European organization for research on treatment of cancer (EORTC) phase II study
B Richards, D Newling, S Fossa, et al.
The Journal of Urology
|
April 1, 1989
Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials
H J de Voogt, S Suciu, R Sylvester, et al.
Biochemistry. Biokhimiia
|
March 1, 1997
Composition and structural and functional properties of discoidal and spherical phospholipid-apoE3 complexes
M De Pauw, B Vanloo, A D Dergunov, et al.
European Journal of Cancer & Clinical Oncology
|
September 1, 1985
Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-urinary Tract Cancer Cooperative Group
A T van Oosterom, S D Fosså, J H Mulder, et al.
European Urology
|
March 31, 1998
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group
H J de Voogt, U Studer, F H Schröder, et al.
Journal of the American College of Cardiology
|
November 3, 2001
Preinfarction angina protects against out-of-hospital ventricular fibrillation in patients with acute occlusion of the left coronary artery
P J Gheeraert, J P Henriques, M L De Buyzere, et al.
The Journal of Urology
|
December 1, 1993
Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865)
D W Newling, S D Fossa, U W Tunn, et al.
The Journal of Urology
|
March 1, 1995
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group
C Bouffioux, K H Kurth, A Bono, et al.
European Urology
|
January 1, 1982
Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone
C C Schulman, M Robinson, L Denis, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 107) with videos related to
Sort By:
Page
of 11
European Journal of Orthodontics
|
January 22, 2022
A non-cephalometric two-dimensional appraisal of soft tissue changes by functional therapy in Class II patients: a systematic review and meta-analysis
Jonathan Luyten, Michiel Vierendeel, Noëmi M C De Roo, et al.
Cancer Treatment Reports
|
June 1, 1983
Vincristine in advanced bladder cancer: a European organization for research on treatment of cancer (EORTC) phase II study
B Richards, D Newling, S Fossa, et al.
The Journal of Urology
|
April 1, 1989
Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials
H J de Voogt, S Suciu, R Sylvester, et al.
Biochemistry. Biokhimiia
|
March 1, 1997
Composition and structural and functional properties of discoidal and spherical phospholipid-apoE3 complexes
M De Pauw, B Vanloo, A D Dergunov, et al.
European Journal of Cancer & Clinical Oncology
|
September 1, 1985
Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-urinary Tract Cancer Cooperative Group
A T van Oosterom, S D Fosså, J H Mulder, et al.
European Urology
|
March 31, 1998
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group
H J de Voogt, U Studer, F H Schröder, et al.
Journal of the American College of Cardiology
|
November 3, 2001
Preinfarction angina protects against out-of-hospital ventricular fibrillation in patients with acute occlusion of the left coronary artery
P J Gheeraert, J P Henriques, M L De Buyzere, et al.
The Journal of Urology
|
December 1, 1993
Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865)
D W Newling, S D Fossa, U W Tunn, et al.
The Journal of Urology
|
March 1, 1995
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group
C Bouffioux, K H Kurth, A Bono, et al.
European Urology
|
January 1, 1982
Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone
C C Schulman, M Robinson, L Denis, et al.
Page
of 11